These complementary products will cover the seven common, harmful parasites that affect dogs inside and out by preventing ticks and multiple stages of the flea lifecycle, including eggs and adult fleas, as well as treating and controlling all common intestinal parasites, including roundworms, hookworms, whipworms and tapeworms and preventing heartworm disease. The BRAVECTO® product line, which are our extended duration flea and tick protection products, and the SENTINEL branded products, which control all common intestinal parasites, provide an attractive opportunity for broad-spectrum, year-round comprehensive internal and external parasite protection for dogs. Merck Animal Health will make a cash payment of approximately $400 million to acquire the SENTINEL branded products in the United States at closing of the acquisition.Ĭomprehensive parasite protection is an essential part of canine overall health and well-being. rights to SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® Chews in the Companion Animal category. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), and Virbac (NYSE Euronext:VIRP) today announced that the companies have signed a definitive agreement under which Merck Animal Health would acquire the U.S. Companion Animal Category with Comprehensive, Continuous Parasite ProtectionĬomplements Merck Animal Health’s Broad Portfolio of Vaccines and Pharmaceuticals Further Solidifies Merck Animal Health’s Position in the U.S.
0 kommentar(er)
